These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
147 related articles for article (PubMed ID: 30825105)
1. A high-throughput drug screen identifies auranofin as a potential sensitizer of cisplatin in small cell lung cancer. Liu X; Wang W; Yin Y; Li M; Li H; Xiang H; Xu A; Mei X; Hong B; Lin W Invest New Drugs; 2019 Dec; 37(6):1166-1176. PubMed ID: 30825105 [TBL] [Abstract][Full Text] [Related]
2. Cisplatin and photodynamic therapy exert synergistic inhibitory effects on small-cell lung cancer cell viability and xenograft tumor growth. Cheng YS; Peng YB; Yao M; Teng JP; Ni D; Zhu ZJ; Zhuang BF; Yang ZY Biochem Biophys Res Commun; 2017 Jun; 487(3):567-572. PubMed ID: 28431928 [TBL] [Abstract][Full Text] [Related]
3. Combination of arsenic trioxide and chemotherapy in small cell lung cancer. Zheng CY; Lam SK; Li YY; Fong BM; Mak JC; Ho JC Lung Cancer; 2013 Nov; 82(2):222-30. PubMed ID: 24041618 [TBL] [Abstract][Full Text] [Related]
4. Gallic acid induces apoptosis and enhances the anticancer effects of cisplatin in human small cell lung cancer H446 cell line via the ROS-dependent mitochondrial apoptotic pathway. Wang R; Ma L; Weng D; Yao J; Liu X; Jin F Oncol Rep; 2016 May; 35(5):3075-83. PubMed ID: 26987028 [TBL] [Abstract][Full Text] [Related]
5. Inhibition of the Replication Stress Response Is a Synthetic Vulnerability in SCLC That Acts Synergistically in Combination with Cisplatin. Nagel R; Avelar AT; Aben N; Proost N; van de Ven M; van der Vliet J; Cozijnsen M; de Vries H; Wessels LFA; Berns A Mol Cancer Ther; 2019 Apr; 18(4):762-770. PubMed ID: 30872379 [TBL] [Abstract][Full Text] [Related]
6. Auranofin inhibition of thioredoxin reductase sensitizes lung neuroendocrine tumor cells (NETs) and small cell lung cancer (SCLC) cells to sorafenib as well as inhibiting SCLC xenograft growth. Johnson SS; Liu D; Ewald JT; Robles-Planells C; Pulliam C; Christensen KA; Bayanbold K; Wels BR; Solst SR; O'Dorisio MS; Menda Y; Spitz DR; Fath MA Cancer Biol Ther; 2024 Dec; 25(1):2382524. PubMed ID: 39054566 [TBL] [Abstract][Full Text] [Related]
7. Synergistic antitumor effect between vorinostat and topotecan in small cell lung cancer cells is mediated by generation of reactive oxygen species and DNA damage-induced apoptosis. Bruzzese F; Rocco M; Castelli S; Di Gennaro E; Desideri A; Budillon A Mol Cancer Ther; 2009 Nov; 8(11):3075-87. PubMed ID: 19887547 [TBL] [Abstract][Full Text] [Related]
8. Study of small-cell lung cancer cell-based sensor and its applications in chemotherapy effects rapid evaluation for anticancer drugs. Guohua H; Hongyang L; Zhiming J; Danhua Z; Haifang W Biosens Bioelectron; 2017 Nov; 97():184-195. PubMed ID: 28599178 [TBL] [Abstract][Full Text] [Related]
9. Chemotherapy-Regulated microRNA-125-HER2 Pathway as a Novel Therapeutic Target for Trastuzumab-Mediated Cellular Cytotoxicity in Small Cell Lung Cancer. Yagishita S; Fujita Y; Kitazono S; Ko R; Nakadate Y; Sawada T; Kitamura Y; Shimoyama T; Maeda Y; Takahashi F; Takahashi K; Tamura T; Koizumi F Mol Cancer Ther; 2015 Jun; 14(6):1414-23. PubMed ID: 25833836 [TBL] [Abstract][Full Text] [Related]
10. Targeting a non-oncogene addiction to the ATR/CHK1 axis for the treatment of small cell lung cancer. Doerr F; George J; Schmitt A; Beleggia F; Rehkämper T; Hermann S; Walter V; Weber JP; Thomas RK; Wittersheim M; Büttner R; Persigehl T; Reinhardt HC Sci Rep; 2017 Nov; 7(1):15511. PubMed ID: 29138515 [TBL] [Abstract][Full Text] [Related]
11. The ratio of Bcl-2/Bim as a predictor of cisplatin response provides a rational combination of ABT-263 with cisplatin or radiation in small cell lung cancer. Li H; Wang H; Deng K; Han W; Hong B; Lin W Cancer Biomark; 2019; 24(1):51-59. PubMed ID: 30614795 [TBL] [Abstract][Full Text] [Related]
12. Exploiting the reactive oxygen species imbalance in high-risk paediatric acute lymphoblastic leukaemia through auranofin. Karsa M; Kosciolek A; Bongers A; Mariana A; Failes T; Gifford AJ; Kees UR; Cheung LC; Kotecha RS; Arndt GM; Haber M; Norris MD; Sutton R; Lock RB; Henderson MJ; Somers K Br J Cancer; 2021 Jul; 125(1):55-64. PubMed ID: 33837299 [TBL] [Abstract][Full Text] [Related]
14. Arsenic trioxide-induced cytotoxicity in small cell lung cancer via altered redox homeostasis and mitochondrial integrity. Zheng CY; Lam SK; Li YY; Ho JC Int J Oncol; 2015 Mar; 46(3):1067-78. PubMed ID: 25572414 [TBL] [Abstract][Full Text] [Related]
15. ESRP1 regulates alternative splicing of CARM1 to sensitize small cell lung cancer cells to chemotherapy by inhibiting TGF-β/Smad signaling. Zheng M; Niu Y; Bu J; Liang S; Zhang Z; Liu J; Guo L; Zhang Z; Wang Q Aging (Albany NY); 2021 Jan; 13(3):3554-3572. PubMed ID: 33495408 [TBL] [Abstract][Full Text] [Related]
16. Auranofin induces apoptosis by ROS-mediated ER stress and mitochondrial dysfunction and displayed synergistic lethality with piperlongumine in gastric cancer. Zou P; Chen M; Ji J; Chen W; Chen X; Ying S; Zhang J; Zhang Z; Liu Z; Yang S; Liang G Oncotarget; 2015 Nov; 6(34):36505-21. PubMed ID: 26431378 [TBL] [Abstract][Full Text] [Related]
17. Resveratrol promotes the sensitivity of small-cell lung cancer H446 cells to cisplatin by regulating intrinsic apoptosis. Li W; Shi Y; Wang R; Pan L; Ma L; Jin F Int J Oncol; 2018 Nov; 53(5):2123-2130. PubMed ID: 30132509 [TBL] [Abstract][Full Text] [Related]
18. [Establishment of A Patient-derived Xenotransplantation Animal Model for Small Cell Lung Cancer and Drug Resistance Model]. Zhu Y; Huang W; Wu Y; Jia L; Li Y; Chen R; Guo L; Chen Q Zhongguo Fei Ai Za Zhi; 2019 Jan; 22(1):6-14. PubMed ID: 30674387 [TBL] [Abstract][Full Text] [Related]
19. Mitochondrial dysfunction rather than mtDNA sequence mutation is responsible for the multi-drug resistance of small cell lung cancer. Ma L; Wang R; Duan H; Nan Y; Wang Q; Jin F Oncol Rep; 2015 Dec; 34(6):3238-46. PubMed ID: 26502806 [TBL] [Abstract][Full Text] [Related]
20. Inhibition of p62/SQSTM1 sensitizes small-cell lung cancer cells to cisplatin-induced cytotoxicity by targeting NEDD9 expression. Xu L; Xu F; Kong Q; Yang T; Tan D; Zhang X; Li N; Zhao S; Zhao J; Li M Mol Carcinog; 2020 Aug; 59(8):967-979. PubMed ID: 32424979 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]